Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction

  • J Med Chem. 2014 Dec 26;57(24):10499-511. doi: 10.1021/jm501550p.
Yosup Rew  1 ,  Daqing Sun ,  Xuelei Yan ,  Hilary P Beck ,  Jude Canon ,  Ada Chen ,  Jason Duquette ,  John Eksterowicz ,  Brian M Fox ,  Jiasheng Fu ,  Ana Z Gonzalez ,  Jonathan Houze ,  Xin Huang ,  Min Jiang ,  Lixia Jin ,  Yihong Li ,  Zhihong Li ,  Yun Ling ,  Mei-Chu Lo ,  Alexander M Long ,  Lawrence R McGee ,  Joel McIntosh ,  Jonathan D Oliner ,  Tao Osgood ,  Anne Y Saiki ,  Paul Shaffer ,  Yu Chung Wang ,  Sarah Wortman ,  Peter Yakowec ,  Qiuping Ye ,  Dongyin Yu ,  Xiaoning Zhao ,  Jing Zhou ,  Julio C Medina ,  Steven H Olson
Affiliations
  • 1. Department of Therapeutic Discovery, ‡Department of Pharmaceutics, and §Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.
PMID: 25384157 DOI: 10.1021/jm501550p
Abstract

Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of Cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 (25), featuring improved potency (KD from ITC competition was 38 pM, SJSA-1 EdU IC50 = 1.6 nM), remarkable pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 Osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD). In addition, 25 possesses distinct mechanisms of elimination compared to 1.

Products